rs141004029
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBS1_SupportingBS2
The NM_018249.6(CDK5RAP2):āc.5152C>Gā(p.Leu1718Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000886 in 1,614,200 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_018249.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDK5RAP2 | NM_018249.6 | c.5152C>G | p.Leu1718Val | missense_variant | 34/38 | ENST00000349780.9 | NP_060719.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CDK5RAP2 | ENST00000349780.9 | c.5152C>G | p.Leu1718Val | missense_variant | 34/38 | 1 | NM_018249.6 | ENSP00000343818.4 |
Frequencies
GnomAD3 genomes AF: 0.000585 AC: 89AN: 152208Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000799 AC: 201AN: 251428Hom.: 0 AF XY: 0.000890 AC XY: 121AN XY: 135880
GnomAD4 exome AF: 0.000917 AC: 1341AN: 1461874Hom.: 4 Cov.: 31 AF XY: 0.000960 AC XY: 698AN XY: 727240
GnomAD4 genome AF: 0.000584 AC: 89AN: 152326Hom.: 0 Cov.: 32 AF XY: 0.000564 AC XY: 42AN XY: 74486
ClinVar
Submissions by phenotype
Microcephaly 3, primary, autosomal recessive Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Uncertain significance, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Nov 16, 2021 | DNA sequence analysis of the CDK5RAP2 gene demonstrated a sequence change, c.5152C>G, in exon 34 that results in an amino acid change, p.Leu1718Val. This sequence change has been described in the gnomAD database with a frequency of 0.12%in the South Asian subpopulation (dbSNP rs141004029). The p.Leu1718Val change affects a moderately conserved amino acid residue located in a domain of the CDK5RAP2 protein that is not known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Leu1718Val substitution. This sequence change does not appear to have been previously described in individuals with CDK5RAP2-related disorders. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Leu1718Val change remains unknown at this time. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Sep 08, 2017 | - - |
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2024 | CDK5RAP2: BP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 22, 2022 | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1718 of the CDK5RAP2 protein (p.Leu1718Val). This variant is present in population databases (rs141004029, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with CDK5RAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 158156). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 02, 2023 | The c.5152C>G (p.L1718V) alteration is located in exon 34 (coding exon 34) of the CDK5RAP2 gene. This alteration results from a C to G substitution at nucleotide position 5152, causing the leucine (L) at amino acid position 1718 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at